GlassScriptPhysician profile
Nicholas Diloreto
NPI 1669165940
$1,814.42
in general payments reported to CMS, 2019-2025
14 companies · $937 in 2025
The $937 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $72.88 · 2024: $804 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.35 | 2024-2025 | Wegovy |
| Boston Scientific Corporation | $286.97 | 2024-2025 | Watchman Flx |
| Amgen INC. | $219.80 | 2025 | Prolia, Evenity, Tepezza |
| Astrazeneca Pharmaceuticals LP | $207.17 | 2024 | Wainua, Fasenra |
| Inari Medical, INC. | $172.42 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $110.46 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $101.83 | 2024 | Camzyos |
| Gilead Sciences, INC. | $97.02 | 2024 | Veklury |
| Penumbra, INC. | $76.17 | 2024 | Indigo System |
| Abbvie INC. | $72.88 | 2023 | Dalvance |
| Janssen Pharmaceuticals, INC | $49.45 | 2024 | Xarelto |
| Janssen Biotech, INC. | $29.43 | 2025 | Tremfya |
| Vivus LLC | $18.11 | 2025 | Qsymia |
| Takeda Pharmaceuticals U.S.A., INC. | $16.36 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Diloreto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.